GlassScriptPhysician profile
Robert G Szewc
NPI 1992759476
$11,276.28
in general payments reported to CMS, 2019-2025
38 companies · $1,639 in 2025
The $1,639 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $215 · 2021: $658 · 2022: $1,069 · 2023: $1,276 · 2024: $6,032 · 2025: $1,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,263 · Travel and Lodging: $3,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,263.31 |
| Travel and Lodging | $3,682.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $2,065.84 | 2024 | |
| Medtronic, INC. | $2,011.26 | 2024-2025 | Ellipsys Vascular Access System, Symplicity G3 |
| Astrazeneca Pharmaceuticals LP | $835.84 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $718.64 | 2020-2025 | Krystexxa, Evenity, Repatha |
| Eli Lilly and Company | $686.18 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $415.85 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $395.97 | 2021-2025 | Lupkynis |
| Outset Medical INC | $354.69 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $352.17 | 2023-2025 | Acthar, Terlivaz |
| Opko Pharmaceuticals, LLC | $339.80 | 2019-2025 | Rayaldee |
| Novo Nordisk INC | $336.59 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Horizon Therapeutics Plc | $289.51 | 2019-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $255.19 | 2021-2024 | Soliris, Ultomiris |
| Otsuka America Pharmaceutical, INC. | $254.32 | 2019-2024 | Jynarque |
| Philips North America LLC | $214.16 | 2019-2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Szewc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.